Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis
Open accessThe DOI matches its Crossref record.
Abstract
Fumaric acid is an intermediate product of the citric acid cycle that is a source of intracellular energy in the form of adenosine triphosphate (ATP). It is generated by oxidation of adenylsuccinate by the enzyme succinate dehydrogenase and is then converted to maleate by the enzyme fumarase. At present, fumaric acid esters (FAE) are licensed for the treatment of psoriasis. Several lines of evidence have demonstrated immunomodulatory effects for FAE. Clinical studies in psoriasis showed a reduction of peripheral CD4(+)- and CD8(+)-T-lymphocytes due to the ability of FAE to induce apoptosis. In vitro studies with the ester dimethyl fumarate (DMF) described an inhibitory effect on nuclear factor kappa B (NF-kappaB)-dependent transcription of tumor necrosis factor-alpha (TNF-alpha) induced genes in human endothelial cells. Animal studies using a model of central nervous system demyelination, MOG-induced experimental autoimmune encephalomyelitis (EAE), revealed a reduction of microglia and macrophages in inflamed lesions. A phase II clinical study in relapsing-remitting multiple sclerosis (RRMS) patients with a modified fumaric acid ester, BG-12, showed as "proof of principle" a significant reduction in the number of gadolinium enhancing lesions after 24 weeks of treatment as compared to placebo. Further phase III studies have now started to explore the long-term efficacy of FAE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A comprehensive metabolic map for production of bio-based chemicals
Lee, S. Y., Kim, H. U., Chae, T. U., Cho, J. S., Kim, J. W., Shin, J. H., Kim, D. I., Ko, Y.-S., Jang, W. D., & Jang, Y.-S. (2019) · Nature Catalysis · doi:10.1038/s41929-018-0212-4 · Cited by 607
Gallagher, F. A., Kettunen, M. I., Hu, D.-E., Jensen, P. R., Zandt, R. I. ‘., Karlsson, M., Gisselsson, A., Nelson, S. K., Witney, T. H., Bohndiek, S. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911447106 · Cited by 301
Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview
Bomprezzi, R. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285614564152 · Cited by 301
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
The benefits and detriments of macrophages/microglia in models of multiple sclerosis
Rawji, K. S., & Yong, V. W. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/948976 · Cited by 217
“It is an oral tablet thought to act by decreasing the expression of NF-κB dependent genes [133, 134].”
Background
Metadata
- Authors
- Moharregh-Khiabani, D., Linker, R., Gold, R., & Stangel, M.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-03-01
- Volume
- 7
- Issue
- 1
- Pages
- 60-64
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W1970068928
- Cited by
- 139
- References
- 0
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis. https://app.cochat.ai/papers/10.2174/157015909787602788
- The paper
- Moharregh-Khiabani, D., Linker, R., Gold, R., & Stangel, M. (2009). Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis. Current Neuropharmacology. https://doi.org/10.2174/157015909787602788
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.